Potier, Louis
Roussel, Ronan
Velho, Gilberto
Saulnier, Pierre-Jean
Bumbu, Anisoara
Matar, Odette
Schneider, Fabrice
Ragot, Stéphanie
Marre, Michel
Mohammedi, Kamel
Hadjadj, Samy
Funding for this research was provided by:
French Ministry of Health (None)
Association Française des Diabetiques
Article History
Received: 19 September 2018
Accepted: 29 January 2019
First Online: 26 February 2019
Duality of interest
: LP reports grants, personal fees and non-financial support from Novo Nordisk and Sanofi, personal fees and non-financial support from Eli Lilly and non-financial support from Servier. RR reports grants, personal fees and non-financial support from Sanofi, personal fees and non-financial support from MSD, grants from Amgen, personal fees from Physiogenex, AstraZeneca, Janssen, Eli Lilly, Abbott, Medtronic, Novo Nordisk and Servier and grants from Novo Nordisk. AB reports non-financial support from Sanofi, Novo Nordisk and Elivie. MM reports personal fees from Abbott, Intarcia, Eli Lilly, MSD, Novo Nordisk, Sanofi and Servier, grants from Novo Nordisk, Sanofi, Servier, MSD and Novartis and non-financial support from Novo Nordisk. KM reports personal fees and non-financial support from Novo Nordisk and Sanofi and non-financial support from VitalAir. SH reports personal fees and non-financial support from AstraZeneca, Bristol-Myers Squibb, Janssen, MSD and Sanofi, personal fees from Abbott, Boehringer Ingelheim, Eli Lily, Novartis, Novo Nordisk, Servier and Takeda. All support was outside the submitted work and modest. All other authors declare that there is no duality of interest associated with their contribution to this manuscript.